Displaying 801 - 820 of 2208
FTC and NY Attorney General Charge Vyera Pharmaceuticals, Martin Shkreli, and Other Defendants with Anticompetitive Scheme to Protect a List-Price Increase of More Than 4,000 Percent for Life-Saving Drug Daraprim
Illumina Inc./Pacific Biosciences of California, Inc., In the Matter of
The Federal Trade Commission authorized an action to block Illumina Inc.’s proposed $1.2 billion acquisition of Pacific Biosciences of California, alleging in an administrative complaint that Illumina is seeking to unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing systems by extinguishing PacBio as a nascent competitive threat. The Commission vote to issue the administrative complaint and to authorize staff to seek a temporary restraining order and preliminary injunction was 5-0. On Jan. 2, 2020, the parties abandoned the transaction.
FTC Seeks Public Comment on Par Petroleum Corp.’s Application to Modify Agreement to Store Petroleum Products at Barbers Point Terminal in Hawaii
Post Holdings, Inc.; In the Matter of
The Federal Trade Commission authorized an action to block Post Holdings, Inc.’s proposed acquisition of the private label ready-to-eat ("RTE") cereal business of TreeHouse Foods, Inc. In an administrative complaint issued on December 19, 2019, the Commission alleges that the proposed acquisition would harm retailers and end consumers by eliminating head-to-head competition between the Respondents in the United States market for private label RTE cereal. The Commission vote to issue the administrative complaint and to authorize staff to seek a temporary restraining order and preliminary injunction was 5-0. The administrative trial is scheduled to begin on May 27, 2020. The parties announced they had abandoned the transaction on Jan. 13, 2020.
Statement of Ian Conner, Director of FTC Bureau of Competition, Regarding the Announcement that Post Holdings, Inc. has Abandoned Its Proposed Acquisition of TreeHouse Foods, Inc.
FTC Publishes Inflation-Adjusted Civil Penalty Amounts
FTC Approves Final Order Requiring Bristol-Myers Squibb Company and Celgene Corporation to Divest Psoriasis Drug Otezla as a Condition of Acquisition
FTC Staff Comment to the Kansas House of Representatives Concerning Kansas House Bill 2412
FTC Staff Comment to the Ohio House of Representatives Concerning Ohio House Bill 177
Joint Vertical Merger Guidelines (Draft Released for Public Comment)
Concurring Statement of Commissioner Christine S. Wilson Concerning the Publication of FTC-DOJ Draft Vertical Merger Guidelines for Public Comment
FTC and DOJ Announce Draft Vertical Merger Guidelines for Public Comment
Statement of Commissioner Rohit Chopra Regarding the Request for Comment on Vertical Merger Guidelines
FTC Challenges Consummated Merger of Companies that Market Body-Worn Camera Systems to Large Metropolitan Police Departments
Statement of Gail Levine, Deputy Director of FTC Bureau of Competition, Regarding the Announcement that Illumina Inc. has Abandoned Its Proposed Acquisition of Pacific Biosciences of California
FTC Alleges Post Holdings, Inc.’s Proposed Acquisition of TreeHouse Foods, Inc.’s Private Label Ready-to-Eat Cereal Business Will Harm Competition
FTC Chairman Simons Announces Senior Appointments in Bureau of Competition
Third Point LLC
Investment advisor Third Point LLC and three funds that it controls have agreed to settle Federal Trade Commission charges that the funds violated the premerger notification and waiting period requirements of the Hart-Scott-Rodino Act, or HSR Act, after they acquired the voting securities of DowDuPont Inc. According to the complaint, on Aug. 31, 2017, the shares of Dow Inc. held by the three Third Point funds – Third Point Partners Qualified L.P., Third Point Ultra, Ltd., and Third Point Offshore Fund Ltd. – converted to shares of the newly formed DowDuPont Inc. following the merger of Dow Inc. and E.I. du Pont de Nemours & Company. The three funds have agreed to collectively pay $609,810 in civil penalties, and they, together with Third Point LLC, will be barred from committing future violations of the HSR Act in connection with corporate consolidations.
FTC Challenges Illumina’s Proposed Acquisition of PacBio
Displaying 801 - 820 of 2208